It also presents the superiority of CD69 and CD40L markers over cytokine concentration, BATs, and in vivo tests in COVID-19 vaccine allergy testing, which might decrease the cost of allergy diagnostics in the future. This evidence concerns the gene CD40LG and Allergy.